Brielle Benyon

The FDA approved pembrolizumab (Keytruda) for the treatment of patients who are unresponsive to Bacillus Calmette-Guerin (BCG) treatment with high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Not taking opioids as prescribed can be extremely risky to patients, but oncology nurses can help.

An expert discusses lung cancer advances from 2020, as well as exciting new research that is underway.

There is still a lack of clear biomarkers in the metastatic renal cell carcinoma space.

We want to hear from you about what you think were the top cancer advances of the last 10 years.

The year – and the decade – are coming to a close. Look back with us at the top web articles of 2019.

Nurses tend to sleep less before a shift, which could impact patient care, according to recent research conducted at NYU Rory Meyers College of Nursing.

An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.

There's a title wave of older adults flooding the healthcare system. Hear from two oncology nurses on how practitioners can be preapred to give high-quality care.

Researchers and clinicians should consider treatment-free survival when analyzing the results of clinical trials, according to one expert.

An expert discusses recent exciting advances in the treatment landscape of metastatic melanoma.

While cytoreductive nephrectomy has been a mainstay in kidney cancer treatment, there are factors to consider before using the procedure on patients with the disease.

Glioblastoma is historically difficult to treat, but recent research shows some potential for immunotherapy/vaccine combinations for these patients.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to abatacept (Orencia) to prevent moderate or severe acute graft-versus-host disease (GvHD) in patients who underwent a hematopoietic stem cell transplant and are not related to their donors, according to Bristol-Myers Squibb, the manufacturer of the drug.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Even if survivors of pediatric neuroblastoma received treatment before 1 year old, they are still at risk for cognitive issues years later.

A study of patients with chronic lymphocytic leukemia looked into the role of treatment and disease itself in cognitive impairment.

Opioids are the go-to treatment for cancer-related pain. But is this mainstay poised to change as the opioid crisis continues to grow?

After being diagnosed with essential thrombocythemia, former NHL referee Kerry Fraser did his best to maintain a positive attitude – and he says his oncology nurses played a huge role in that.

Patients – and their caregivers too – should be key players in their multiple myeloma treatment planning.

While immunotherapy can be a life-saving approach for many patients with cancer, there are some cardiac adverse events that nurses should look out for.

An expert discusses 2 new surgical treatments for breast cancer-associated lymphedema.

In this episode of CURE Talks Cancer Podcast: Nursing Edition we speak with an oncology nursing expert on a topic not addressed enough, workplace violence.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

One expert discusses how immunotherapy is changing the treatment – and adverse event – landscape in oncology.

A certified genetic counselor discusses the role of genetic testing in gastrointestinal cancers.

Patients are getting a ton of information from outside sources and advertisements about new immunotherapy agents. It is crucial that providers offer them the key facts that they need.

This week, Johnson & Johnson was ordered to pay $572 million for contributing to the opioid crisis in the state of Oklahoma.

While the US Preventative Services Task Force expanded their recommendations of who should be tested for BRCA mutations, there are still issues left unaddressed, according to one expert.

Nurses must stay up to date with the fast-moving world of bladder cancer.